Aclaris Therapeutics’ (ACRS) “Neutral” Rating Reiterated at HC Wainwright

Aclaris Therapeutics (NASDAQ:ACRS)‘s stock had its “neutral” rating restated by analysts at HC Wainwright in a research report issued to clients and investors on Tuesday, Benzinga reports.

Separately, StockNews.com raised Aclaris Therapeutics from a “sell” rating to a “hold” rating in a research note on Thursday, July 25th. Seven investment analysts have rated the stock with a hold rating and one has assigned a buy rating to the stock. According to data from MarketBeat.com, Aclaris Therapeutics has a consensus rating of “Hold” and an average target price of $23.00.

Aclaris Therapeutics Trading Down 0.4 %

Shares of ACRS stock traded down $0.01 on Tuesday, reaching $1.19. The company had a trading volume of 59,049 shares, compared to its average volume of 1,064,541. The stock has a market cap of $84.45 million, a PE ratio of -1.09 and a beta of 0.21. The company has a 50-day moving average of $1.24 and a 200-day moving average of $1.21. Aclaris Therapeutics has a 12 month low of $0.59 and a 12 month high of $7.54.

Aclaris Therapeutics (NASDAQ:ACRS) last issued its earnings results on Wednesday, August 7th. The biotechnology company reported ($0.15) EPS for the quarter, beating the consensus estimate of ($0.19) by $0.04. The firm had revenue of $2.77 million during the quarter, compared to the consensus estimate of $1.74 million. Aclaris Therapeutics had a negative net margin of 183.28% and a negative return on equity of 53.18%. Sell-side analysts anticipate that Aclaris Therapeutics will post -0.65 earnings per share for the current year.

Insider Buying and Selling

In related news, major shareholder Braden Michael Leonard bought 107,434 shares of Aclaris Therapeutics stock in a transaction that occurred on Monday, July 1st. The stock was purchased at an average cost of $1.14 per share, with a total value of $122,474.76. Following the purchase, the insider now owns 13,095,572 shares in the company, valued at $14,928,952.08. The acquisition was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Insiders have purchased a total of 930,502 shares of company stock worth $1,119,232 over the last ninety days. Company insiders own 6.40% of the company’s stock.

Hedge Funds Weigh In On Aclaris Therapeutics

A number of large investors have recently bought and sold shares of ACRS. SG Americas Securities LLC lifted its position in shares of Aclaris Therapeutics by 69.5% in the first quarter. SG Americas Securities LLC now owns 32,843 shares of the biotechnology company’s stock worth $41,000 after purchasing an additional 13,461 shares in the last quarter. BNP Paribas Financial Markets increased its stake in Aclaris Therapeutics by 10.9% in the 1st quarter. BNP Paribas Financial Markets now owns 241,101 shares of the biotechnology company’s stock valued at $299,000 after buying an additional 23,747 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. bought a new stake in Aclaris Therapeutics during the 1st quarter worth about $39,000. Russell Investments Group Ltd. boosted its stake in shares of Aclaris Therapeutics by 5,265.1% during the 1st quarter. Russell Investments Group Ltd. now owns 62,772 shares of the biotechnology company’s stock worth $78,000 after buying an additional 61,602 shares during the last quarter. Finally, Millennium Management LLC boosted its stake in shares of Aclaris Therapeutics by 1.9% during the 2nd quarter. Millennium Management LLC now owns 3,336,850 shares of the biotechnology company’s stock worth $3,671,000 after buying an additional 63,358 shares during the last quarter. Institutional investors and hedge funds own 98.34% of the company’s stock.

About Aclaris Therapeutics

Aclaris Therapeutics, Inc a clinical-stage biopharmaceutical company, engages in the development of novel drug candidates for immune-inflammatory diseases in the United States. The company operates through two segments, Therapeutics and Contract Research. The Therapeutics segment is involved in identifying and developing therapies to address significant unmet needs for immuno-inflammatory diseases.